ASP-II: Ancrod Stroke Program: Ancrod (Viprinex™) for the Treatment of Acute, Ischemic Stroke
Status:
Terminated
Trial end date:
2008-12-01
Target enrollment:
Participant gender:
Summary
The primary purpose of this study is to determine whether a brief intravenous infusion of
ancrod started within 6 hours of stroke onset improves functional outcome at 3 months.